Result of AGM

RNS Number : 9194F

N4 Pharma PLC

24 March 2022

 

24 March 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Result of Annual General Meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed. The results of the proxy voting for the AGM are set out below.

Resolution (*Special Resolution)	Total Shares Voted	Shares		%
		For	Against	For	Against
1. To receive the annual report and audited accounts for the year ended 31 December 2021	20,171,351	20,171,151	200	99.999	0.001
2. To re-elect Nigel Theobald as a Director of the Company	20,195,551	20,026,641	168,910	99.164	0.836
3. To re-elect David Templeton as a Director of the Company	20,195,551	20,016,641	178,910	99.114	0.886
4. To re-appoint Saffery Champness LLP as auditor to the company and authorise the directors to determine their remuneration	20,193,244	19,930,222	263,022	98.697	1.303
5. To authorise the Directors to allot shares	20,192,844	19,694,856	497,988	97.534	2.466
6*. To disapply pre-emption rights	20,190,444	19,928,374	262,070	98.702	1.298

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director	Via IFC Advisory
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking)	Tel: + 44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker	Tel: [phone]
IFC Advisory Limited Financial PR Graham Herring Zach Cohen	Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

RAGBBGDXCDDDGDS